Image-guided cryoablation of endophytic renal tumors: technical considerations and current clinical outcomes-a...

Image-guided percutaneous cryoablation (CA) has become an increasingly accepted nephron-sparing treatment for small renal masses, including complex endophytic tumors. This narrative review synthesizes current evidence on technical considerations, oncologic outcomes, and safety profiles of CA for endophytic renal cell carcinoma (RCC), with critical evaluation of factors influencing local tumor control and complications. Dedicated endophytic cohorts report primary 5-year local tumor progression-free survival of approximately 64%-75%, improving to 87%-89% after re-ablation, with excellent cancer-specific survival and minimal impact on renal function. However, high anatomical complexity, size, and proximity to vascular or collecting system structures that suggest more endophytic locations pose significant technical challenges; furthermore, they are associated with increased risk of incomplete ablation and major complications compared with exophytic or mixed tumors. Advances in procedural techniques-including hydrodissection, pyeloperfusion, transarterial embolization, and selective arterial balloon occlusion-have expanded the boundaries of safely treatable disease. CA demonstrates similar safety and renal function preservation vs. partial nephrectomy, without the increase in rates of major adverse events or longer hospitalization. For appropriately selected patients with clinical T1 endophytic RCC, image-guided CA provides a safe and effective therapeutic option with durable oncologic outcomes and substantial quality-of-life benefits. Ongoing multicenter registry data and prospective studies are needed to refine risk stratification and optimize procedural strategies for challenging tumor locations.